CN114642668A - Novel medicinal application of latanoprost - Google Patents
Novel medicinal application of latanoprost Download PDFInfo
- Publication number
- CN114642668A CN114642668A CN202011517930.6A CN202011517930A CN114642668A CN 114642668 A CN114642668 A CN 114642668A CN 202011517930 A CN202011517930 A CN 202011517930A CN 114642668 A CN114642668 A CN 114642668A
- Authority
- CN
- China
- Prior art keywords
- latanoprost
- pharmaceutically acceptable
- cardiomyocytes
- myocardial
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 title claims abstract description 54
- 229960001160 latanoprost Drugs 0.000 title claims abstract description 51
- 230000002107 myocardial effect Effects 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 230000035755 proliferation Effects 0.000 claims abstract description 11
- 230000001737 promoting effect Effects 0.000 claims abstract description 11
- 230000004663 cell proliferation Effects 0.000 claims abstract description 8
- 208000019622 heart disease Diseases 0.000 claims abstract description 7
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 230000005779 cell damage Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000006727 cell loss Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- -1 phenyl-substituted propyl Chemical group 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 1
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a medicinal application of latanoprost. The application is the application of latanoprost or pharmaceutically acceptable salt thereof in preparing a medicament for promoting myocardial cell proliferation. Experiments prove that the latanoprost can promote the rat myocardial cell proliferation. Therefore, the latanoprost can be used for preparing medicaments for promoting the proliferation of myocardial cells, medicaments for treating or preventing heart diseases and other related fields, and provides a new medicament and a new treatment idea for treating or preventing heart diseases such as myocardial infarction.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a new medicinal application of latanoprost.
Background
Cardiovascular diseases have become the first killer threatening human health currently, and 4000 million heart failure patients worldwide have become the main cause of human death. It has been found that in mammals, cardiomyocytes gradually lose proliferative capacity after adult life, and once myocardial infarction occurs, the loss of cardiomyocytes cannot be reversed. About 20-40 million myocardial cells exist in adults, about 25% of myocardial cells are lost within hours after the occurrence of myocardial infarction, the proliferation capacity of the remaining myocardial cells is very limited and is not enough to recover the systolic function of the heart, and finally, the heart failure of patients dies. To solve this problem, besides surgery, basic transformation studies mainly include finding cardiac stem cells or precursor cells, transplanting the cells to the myocardial infarction area by induced differentiation, but lack of sufficient molecular markers and low transplantation efficiency limit the use of this technology; the fibroblasts are transdifferentiated into cardiomyocytes using reprogramming techniques, or supplemented to the missing myocardium by means of promoting endogenous cardiomyocyte proliferation. The existing research shows that the heart of lower vertebrates such as zebra fish, salamander and the like has strong regeneration capacity, and newborn suckling mice also have certain regeneration capacity, and the regeneration capacity is mainly realized through myocardial cell proliferation induced by injury, and the capacity disappears after the adult. Adult hearts have not been considered to regenerate in the past, but extensive evidence suggests that there is a slow renewal of mammalian cardiomyocytes, and studies have found that neonatal cardiomyocytes are derived from existing myocardium. Therefore, an increasing number of scientists are interested in a strategy that induces the proliferation of endogenous cardiomyocytes. Therefore, the search for drugs capable of inducing the proliferation of endogenous cardiac muscle cells is of great significance for the treatment of cardiovascular diseases of human beings.
Latanoprost (latanoprost) is a novel phenyl-substituted propyl ester prostaglandin F2a, a selective F2a receptor agonist. It is an inactive but rapidly penetrating substance into the cornea, which can be hydrolyzed to the active free acid in the cornea and plasma. It can increase the outflow of aqueous humor through the keratin layer of eye, and has small dosage, but can promote the outflow of aqueous humor to be large, so that the liquid medicine can permeate into the supraciliary choroid of eyeball, and has good effect of reducing intraocular pressure. However, there is no report on the induction of endogenous cardiomyocyte proliferation by latanoprost.
Disclosure of Invention
The invention aims to provide a new application of latanoprost (latanoprost) or pharmaceutically acceptable salts thereof.
The latanoprost (latanoprost), CAS No.130209-82-4, has a structural formula shown in formula I:
the new application of latanoprost or pharmaceutically acceptable salts thereof provided by the invention is application of latanoprost in preparation of products for promoting myocardial cell proliferation.
The cardiomyocytes can be human or mammalian cardiomyocytes. The product may be a pharmaceutical product.
The invention also aims to provide application of latanoprost (latanoprost) or pharmaceutically acceptable salts and esters thereof in preparing products for preventing and/or treating cardiovascular diseases. The product may be a pharmaceutical product.
Further, in some embodiments of the invention, the cardiovascular disease may be a heart disease resulting from loss, injury or death of cardiomyocytes.
Further, in some embodiments of the present invention, the above-mentioned heart diseases include, but are not limited to, myocardial infarction, heart failure, and other cardiomyopathies resulting from loss, injury, or death of cardiomyocytes, and the like.
Products prepared by taking latanoprost (latanoprost) or pharmaceutically acceptable salts thereof as active ingredients and used for promoting myocardial cell proliferation and products prepared for preventing and/or treating cardiovascular diseases also belong to the protection scope of the invention.
When necessary, one or more pharmaceutically acceptable carriers can be added into the medicine; the carrier includes diluent, excipient, filler, binder, wetting agent, disintegrating agent, absorption enhancer, surfactant, adsorption carrier, lubricant, etc. which are conventional in the pharmaceutical field.
The above medicine can be made into various forms such as injection, tablet, powder, granule, capsule, oral liquid, paste, cream, etc.; the medicaments in various dosage forms can be prepared according to the conventional method in the pharmaceutical field.
The above drugs can be introduced into body such as muscle, intradermal, subcutaneous, intravenous, mucosal tissue by injection, spray, nasal drop, eye drop, penetration, absorption, physical or chemical mediated method; or mixed or coated with other materials and introduced into body.
It is still another object of the present invention to provide a method for culturing cardiomyocytes in vitro.
The method for culturing the myocardial cells in vitro comprises the step of adding latanoprost or pharmaceutically acceptable salt thereof into a culture medium containing the myocardial cells.
The final concentration of latanoprost (latanoprost) or a pharmaceutically acceptable salt thereof in the medium is 0.5-2 μmol/L. The cardiomyocyte can be a human or mammalian cardiomyocyte.
The invention also provides a method for promoting the proliferation of the myocardial cells in vitro.
The method for promoting the proliferation of the myocardial cells in vitro comprises the step of treating the myocardial cells with latanoprost (latanoprost) or pharmaceutically acceptable salts thereof.
The concentration of latanoprost (latanoprost) or a pharmaceutically acceptable salt thereof in the treatment system is 0.5-2 μmol/L. The cardiomyocytes can be human or mammalian cardiomyocytes.
Experiments prove that latanoprost (latanoprost) can promote rat myocardial cell proliferation. Therefore, latanoprost can be used for preparing related fields such as medicines for promoting myocardial cell proliferation and medicines for treating or preventing heart diseases, and provides a new medicine and a new treatment idea for treating or preventing heart diseases such as myocardial infarction.
Drawings
FIG. 1 is a graph showing the effect of latanoprost (latanoprost) on the proliferation of cardiomyocytes in newborn rats.
Detailed Description
The present invention will be further illustrated with reference to the following specific examples, but the present invention is not limited to the following examples. The method is a conventional method unless otherwise specified. The starting materials are commercially available from the open literature unless otherwise specified.
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Latanoprost (latanoprost) used in the following examples was a DMSO solution of Latanoprost (latanoprost). Latanoprost manufacturer TargetMol, cat # T2528.
In the following examples "FBS" is fetal bovine serum.
The cTnT-mAG-hGeminin (1/110) virus used in the following examples was constructed as follows:
the cTnT myocardial specific promoter (shown as a sequence 1 in a sequence table) and mAG-hGeminin (1/110) (GenBank: NM-015895) are assembled and cloned on a pShuttle vector (Addgene 16402) by pEASY-Uni Seamless Cloning and Assembly Kit (all-type gold CU101-01), and then are subjected to enzyme digestion by a restriction enzyme PmeI to collect a linear plasmid; the linearized plasmid was co-transformed with pAdEasy1 DNA (Addgene 16400) to BJ5183 competent, recombinant plasmid was selected and amplified, and 293A cells were transfected with the recombinant plasmid (7.5X 10 cells were transfected the day before transfection)5293A cells were plated in a 60mm dish and cultured in DMEM medium containing 5% fetal bovine serum until the cell count reached 1.0-1.5X 106Then, transfecting the cells with the recombinant plasmid by using a calcium phosphate coprecipitation method, removing a culture solution containing coprecipitation particles the next day after transfection, washing with a PBS buffer solution, subpackaging the cells into a 6-hole plate (3 ml of DMEM culture solution containing 5% fetal calf serum is added into each hole), and standing for 6 hours to allow the cells to adhere to the wall; 6 hoursPost-covering the agarose for virus plaque formation (plaques should form within 10-21 days, adding agarose/DMEM mixture every 4-5 days or when the medium turns yellow); after obtaining the initial virus, the adenovirus is purified by 2-3 rounds of amplification and cesium chloride density gradient centrifugation.
Example 1 in vitro test for Latanoprost (latanoprost) promoting proliferation of rat cardiomyocytes
(1) Culture of cardiac muscle cells of SD rat
Cardiomyocytes from 3-day-old SD rats were isolated and cultured in DMEM high-sugar medium (Hyclone) + 5% horse serum (GIBCO) in a 37-degree, 5% carbon dioxide incubator.
(2) Experimental grouping and processing
The myocardial cells of SD rats were isolated, and 5% horse serum (GIBCO) + DMEM high-sugar medium culture (Hyclone) was added, cytarabine (final concentration 20umol/L) was added to suppress the growth of non-myocardial cells, cells were infected with cTnT-mAG-hGeminin (1/110) virus (MOI value of virus infection: 100) after 48 hours of attachment, and then changed to DMEM containing 0.5% FBS after 24 hours, and the cells were subjected to the divided-dose treatment, as follows:
a. experimental groups: galaptanoprost (latanoprost) treatment (final concentration in medium 2. mu. mol/L) for 24 hours.
b. Blank control group: the same amount of DMSO as in the a experiment group was added.
(3) Test method
After the above 2 groups were treated for 24 hours, nuclei were stained with hoechst fluorescent dye, and then photographed with a high content living cell analyzer (Molecular Device), and mAG-hGeminin (1/110) positive cardiomyocytes and total cell numbers were analyzed.
(4) Results
The test results are shown in FIG. 1. As can be seen in FIG. 1, mAG-hGeminin (1/110) -positive cardiomyocytes increased 3.7-fold after latanoprost (latanoprost) treatment compared to the blank control group (0.5% FBS + DMSO). Mean ± SEM; p < 0.001.
SEQUENCE LISTING
<110> Xin Youkang pharmaceutical technology (Nanjing) Limited Nanjing Jingruikang molecular pharmaceutical technology Limited
New medicinal application of <120> latanoprost
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 836
<212> DNA
<213> Artificial sequence
<400> 1
tgtagttaat gattaacccg ccatgctact tatctaccag ggtaatgggg atcctctaga 60
actatagcta gaattcgccc ttacgggccc cccctcgagg tcgggataaa agcagtctgg 120
gctttcacat gacagcatct ggggctgcgg cagagggtcg ggtccgaagc gctgccttat 180
cagcgtcccc agccctggga ggtgacagct ggctggcttg tgtcagcccc tcgggcactc 240
acgtatctcc gtccgacggg tttaaaatag caaaactctg aggccacaca atagcttggg 300
cttatatggg ctcctgtggg ggaaggggga gcacggaggg ggccggggcc gctgctgcca 360
aaatagcagc tcacaagtgt tgcattcctc tctgggcgcc gggcacattc ctgctggctc 420
tgcccgcccc ggggtgggcg ccggggggac cttaaagcct ctgcccccca aggagccctt 480
cccagacagc cgccggcacc caccgctccg tgggacgatc cccgaagctc tagagcttta 540
ttgcggtagt ttatcacagt taaattgcta acgcagtcag tgcttctgac acaacagtct 600
cgaacttaag ctgcagaagt tggtcgtgag gcactgggca ggtaagtatc aaggttacaa 660
gacaggttta aggagaccaa tagaaactgg gcttgtcgag acagagaaga ctcttgcgtt 720
tctgataggc acctattggt cttactgaca tccactttgc ctttctctcc acaggtgtcc 780
actcccagtt caattacagc tcttaaggct agagtactta atacgactca ctatag 836
Claims (10)
1. The application of latanoprost or pharmaceutically acceptable salts thereof in preparing products for promoting myocardial cell proliferation;
the latanoprost, CAS No. 130209-82-4.
2. Use according to claim 1, characterized in that: the cardiac muscle cell is human or mammalian cardiac muscle cell.
3. The application of latanoprost or pharmaceutically acceptable salts thereof in preparing products for preventing and/or treating cardiovascular diseases; the latanoprost, CAS No. 130209-82-4.
4. Use according to claim 3, characterized in that: the cardiovascular disease is heart disease caused by myocardial cell loss, damage or death due to various reasons.
5. Use according to any one of claims 1 to 4, characterized in that: the product is a medicine.
6. A method for culturing cardiomyocytes in vitro comprising adding latanoprost or a pharmaceutically acceptable salt thereof to a culture medium comprising cardiomyocytes.
7. The method of claim 6, wherein: the final concentration of the latanoprost or a pharmaceutically acceptable salt thereof in the culture medium is 0.5-2 μmol/L.
8. A method of promoting cardiomyocyte proliferation in vitro comprising treating cardiomyocytes with latanoprost or a pharmaceutically acceptable salt thereof.
9. The method of claim 8, wherein: the concentration of the latanoprost or the pharmaceutically acceptable salt thereof in the treatment system is 0.5-2 mu mol/L.
10. The method according to any one of claims 7-9, wherein: the cardiac muscle cell is human or mammalian cardiac muscle cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011517930.6A CN114642668B (en) | 2020-12-21 | 2020-12-21 | New pharmaceutical application of latanoprost |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011517930.6A CN114642668B (en) | 2020-12-21 | 2020-12-21 | New pharmaceutical application of latanoprost |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114642668A true CN114642668A (en) | 2022-06-21 |
| CN114642668B CN114642668B (en) | 2024-04-05 |
Family
ID=81991116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011517930.6A Active CN114642668B (en) | 2020-12-21 | 2020-12-21 | New pharmaceutical application of latanoprost |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114642668B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1684975A (en) * | 2002-08-01 | 2005-10-19 | 阿瑞那制药公司 | Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
-
2020
- 2020-12-21 CN CN202011517930.6A patent/CN114642668B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1684975A (en) * | 2002-08-01 | 2005-10-19 | 阿瑞那制药公司 | Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
Non-Patent Citations (3)
| Title |
|---|
| JADINE LAI等: "Prostaglandin F 2ar induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo", THE AMERICAN PHYSIOLOGICAL SOCIETY, pages 2197 * |
| JOHN W. ADAMS等: "Prostaglandin F2a Stimulates Hypertrophic Growth of Cultured Neonatal Rat Ventricular Myocytes*", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 2, pages 1179 - 1186 * |
| PRIYA KUNAPULI等: "Prostaglandin F2a (PGF2a) and the Isoprostane, 8,12-iso-Isoprostane F2a-III, Induce Cardiomyocyte Hypertrophy", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 35, pages 22442 - 22452 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114642668B (en) | 2024-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021174738A1 (en) | Bionic nanoparticle coated with mesenchymal stem cell membrane having surface overexpressing pd-l1 molecule, and preparation therefor and application thereof | |
| KR101524079B1 (en) | Method for inducing differentiation of adult cells into insulin producing cells using exosome | |
| CN109589337B (en) | Myocardial cell preparation and preparation method and application thereof | |
| CN111374975A (en) | Medicinal application of harmine | |
| WO2014065348A1 (en) | Novel method for treating spinal cord injury using hmgb1 fragment | |
| CN109294980B (en) | Application of rhodiola rosea and salidroside in directional differentiation of stem cells into myocardial-like cells | |
| US11622964B2 (en) | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof | |
| Quan et al. | Thymosin β4 promotes the survival and angiogenesis of transplanted endothelial progenitor cells in the infarcted myocardium | |
| WO2022135278A1 (en) | Novel application of azd3965 medicine | |
| CN113897337A (en) | Method for regulating polarization state of macrophage | |
| CN114712367A (en) | New pharmaceutical application of VO-OHIPIC trihydrate | |
| CN112494494B (en) | Novel pharmaceutical application of BML-28-4 | |
| US20240034997A1 (en) | Myogenin-expressing fibroblast-like cell (meflc) line and construction method and use thereof | |
| WO2022247848A1 (en) | Preparation method for and application of hair follicle mesenchymal stem cell | |
| CN114642668B (en) | New pharmaceutical application of latanoprost | |
| CN113842389B (en) | Pharmaceutical composition for preventing and/or treating cardiovascular diseases | |
| CN116270451A (en) | Fresh mesenchymal stem cell injection and preparation method thereof | |
| CN112516146B (en) | Novel medicinal application of AZ191 | |
| CN114652717B (en) | Pharmaceutical application of naphazoline hydrochloride | |
| CN112603914B (en) | New application of phenylephrine hydrochloride medicament | |
| CN114642662B (en) | Pharmaceutical use of MK-5046 | |
| CN112587530B (en) | Novel pharmaceutical application of Baricitinib | |
| CN104524599A (en) | Antisense nucleotide MiRNA-532 containing pharmaceutical composition and application thereof | |
| CN114984219A (en) | Application of PD1 inhibitor in preparation of cardiac fibroblast transdifferentiation inhibitor | |
| CN112587513A (en) | New application of noradrenaline medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |